- Home
- CRIS vs LABT Comparison
CRIS vs LABT Comparison
Compare CRIS & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | LABT |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.2M |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CRIS | LABT |
|---|---|---|
| Price | $0.39 | $0.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | 223.6K | ★ 532.1K |
| Earning Date | 11-05-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.33 | $0.56 |
| 52 Week High | $3,360.00 | $6.85 |
Technical Indicators
Market Signals| Indicator | CRIS | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 18.80 | 20.28 |
| Support Level | $0.34 | N/A |
| Resistance Level | $5.50 | $2.13 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.77 | 0.01 |
| Stochastic Oscillator | 14.17 | 6.89 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.